Solid Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Solid Biosciences Inc. (SLDB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-19
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.30%.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-09-30 was 4.30%.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-06-30 was 3.90%.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 0.00% change from fiscal 2024.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.40%, a 10.20% decline from fiscal 2023.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.90%, a 25.64% increase from fiscal 2022.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.90%, a 178.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.40% 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 4.40% 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | 4.40% 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | 4.40% 10-K · filed 2026-03-19 | |||
| 2024-09-30 | 4.40% 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | 4.40% 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 4.90% 10-K · filed 2025-03-06 | |||
| 2023-09-30 | 4.30% 10-Q · filed 2024-11-06 | 4.30% 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 3.90% 10-Q · filed 2024-08-13 | 4.20% 10-Q · filed 2024-08-13 | ||
| 2022-12-31 | 3.90% 10-K · filed 2024-03-13 | |||
| 2021-12-31 | 1.40% 10-K · filed 2024-03-13 | |||
| 2020-12-31 | 3.40% 10-K · filed 2023-03-23 | |||
| 2019-12-31 | 2.60% 10-K · filed 2022-03-14 | |||
| 2018-12-31 | 3.10% 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |